Category Archives: Cf

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Protalix BioTherapeutics, Inc. (NYSE: PLX) announced positive results from the Companys phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis (CF). Sixteen patients were enrolled in the study, all of whom completed the study. alidornase alfa is a plant cell-expressed, chemically-modified recombinant DNase enzyme resistant to inhibition by actin, which the Company has specifically designed to enhance the enzymes efficacy in CF patients.

The phase II trial is a 28-day switchover study to evaluate the safety and efficacy of alidornase alfa in CF patients previously treated with Pulmozyme (currently the only commercially available DNase therapy). Participation in the trial was preceded by a two-week washout period from Pulmozyme before treatment with alidornase alfa via inhalation.

The primary efficacy results show that treatment with alidornase alfa resulted in clinically meaningful lung function improvement, as demonstrated by a mean absolute increase in the percent predicted forced expiratory volume in one second (ppFEV1) of 3.4 points from baseline. Moreover, a mean absolute increase in ppFEV1 of 2.8 points was also observed in patients participating in the trial when compared to measurements taken from patients at initiation before the switch from Pulmozyme to alidornase alfa.

A commercially available small molecule CFTR modulator for the treatment of CF has reported a mean absolute increase in ppFEV1 of 2.5 from baseline in its registration clinical study. This score was achieved while 74% of the patients participating in the trial of the CFTR modulator were also treated with the modulator on top of Pulmozyme. While this marketed CFTR addresses a certain mutation applicable to less than 50% of CF patients, alidornase alfa is being developed to treat all CF patients.

Sputa available DNA samples were analyzed for approximately half of the patients. A mean reduction of over 70% in DNA content from baseline was observed, and a mean reduction of over 90% from baseline was observed for sputa visco-elasticity. Correlation between improvement in sputa parameters and pulmonary function was observed.

In addition, an in vitro study of alidornase alfa demonstrated a significant inhibition of Pseudomonas Aeruginosa, with alidornase alfa treated colonies reduced by over 50%, compared to baseline. Pseudomonas, strains of bacteria that are widely found in the environment, are a major cause of lung infections in CF patients. Chronic pulmonary infection is a leading cause of morbidity and mortality in CF patients, despite the aggressive use of antibiotics, and Pseudomonas is the most prevalent organism in the airway colonization of CF patients.

PK analysis performed indicated alidornase alfa is not absorbed into a patients circulatory system, suggesting higher levels of alidornase alfa remains available in the patient's lungs. This provides further support for the potential that alidornase alfa may offer additional efficacy to CF patients.

The above-mentioned material decrease in visco-elasticity and DNA presence in CF patients sputa, coupled with the significant inhibition of Pseudomonas and higher levels of alidornase alfa available in the patients lungs, provides further supportive evidence of improved lung function after treatment with alidornase alfa, as demonstrated by the increase in FEV1.

alidornase alfa was well tolerated with no serious adverse events reported, and all adverse events that occurred during the study were mild and transient in nature.

The efficacy and safety results of alidornase alfa are very encouraging as they demonstrate data that are clinically relevant which brings new hope to CF patients living with this devastating disease, said Professor Eitan Kerem, Chairman of Pediatrics, Head of The Cystic Fibrosis Center, Hadassah University Hospital, and a Principal Investigator in the clinical trial. I look forward to taking part in future clinical studies of alidornase alfa as I believe it has the potential to become a gold standard treatment for all CF patients.

We are very excited with the clinical data showing a significant, clinically meaningful improvement in efficacy, and potentially offering new alternatives to all CF patients, commented Moshe Manor, Protalixs President and Chief Executive Officer. We look forward to exploring different paths for advancing the clinical development of alidornase alfa.

Data from the study was accepted as an oral presentation at the 40th European Cystic Fibrosis Conference to be held in June 2017.

Read the original here:

Protalix BioTherapeutics (PLX) Phase II Trial of alidornase alfa Shows Positive Results in CF - StreetInsider.com

The technicals for CF Industries Holdings, Inc. (CF) has spoken via its technical chart and the message is loud and clear. Based on that message, this is the relevant information necessary to make sense of that current setup. Technical charts and data play a much bigger role in the success of traders than most would believe. Theres simply no better way to get the full message being sent by a stock than through reading its technical chart accurately. Its a principle worth keeping in mind as a trader looks to profit from a stock.

(CF) is now solidly presented where a clearly defined trend is concerned. This is evident based on information displayed via its 50 and 200 SMAs. The trend levels paint a telling picture which when analyzed, is best characterized as bullish. As a result of the current trends presented by both SMAs, traders have offered a defined and strong outlook for the stock. The overall sentiment or disposition towards the stock can best be described as positive. The discernable sentiment towards the stock has created a resulting influx of opinion that is now created a volume situation clearly titling towards a weak disposition as the situational flux between buyers and sellers take a definitive shape. The overall sentiment of the stock certainly looks more shapely than it did before the foregoing technical indicators started to converge. The trend seems like a likely candidate for becoming something bigger.; Since these sentiments have taken shape, a marked level of indifference has materialized when all statistical factors are considered regarding the stocks profile among traders. Overall viability is therefore, based on the foregoing readings, highlighting the disposition of traders towards the stock. This disposition should retain consistency with the overall technical picture cast by the two important technical indicators mentioned above.

Relative strength indicator (RSI) and Stochastic measures offer another dimension to the whole methodology of analyzing a stock for its potential and existing trends. Both measures are relied upon heavily by successful traders, and combined; they offer an insightful peek inside the workings of a stock. They specifically allow traders to gauge whether or not a given stock is overbought or oversold. The overbought/undersold measure should never be underestimated for it allows a trader to see where the directional bearings are for a given stock. Are buyers more represented? Are sellers dominating? Both these indicators help I determining this general direction of the marketplace. CFs prevailing reading for its 14-day RSI is 48.90%; this means, on current reading, that the stock is neutral, suggesting that the stock is relatively stable in terms of potential price directional movement in either direction. The stochastic reading offers a supplementary outlook for directional movement of CF. Stochastic readings amassed over the last thirty days have created a score of 51.91%. This indicates that the stock is neither overbought or oversold at current levels.

Adding other technical indicators to a trading strategy can often lead to bigger results. These additional indicators, especially the ones tied to performance, can go a long way in providing a surer path to success. A picture is by now surely emerging on the directional thrust of (CF); that emerging picture is proving to be a magnet for traders that have previously shown an interest. The +0.44 has manifested a positive reading in the last month or so of trading since it began its initial directional move. Longer-term, the stock has outperform the S&P 500 by -10.8%. This has created higher daily volatility when matched with stocks of the same class. Things look the same when measured historically. Historical volatility provides a measure of 35.03%. CF therefore offers a handy picture of overall momentum based on the foregoing measures. The last, but certainly not least, indicator that helps paint the overall picture of viability is the average true range which is currently 3.37. Combined, all the indicators when synchronized properly can yield excellent trading results.

CFs market machinations have now been laid bare. All the technicals dissected above have now revealed their hand and any trader can see what they should do with the stock. Only a fool would ignore these powerful messages.

Read the original:

The Technical Chart For CF Industries Holdings, Inc. (CF) Is Very Revealing Today - NY Stock News

Valencia CF set to open New York academy SportsPro Media Valencia CF set to open New York academy. Top-tier Spanish soccer side Valencia CF will open their first academy in the United States later this year after signing an agreement with Long Island University. The New York-based VCF Academy will be the ... and more »

Originally posted here:

Valencia CF set to open New York academy - SportsPro Media

DETROIT -- Jackie Bradley Jr. thinks he can avoid a trip to the disabled list. Just to be sure, the Red Sox are sending their center fielder back to Boston.

Bradley was diagnosed Sunday with a sprained ligament in his right knee, the result of losing his footing while rounding first base in the ninth inning one day earlier. The knee appeared stable upon an initial examination by doctors at Comerica Park, but after he woke up Sunday with swelling and stiffness, Bradley went for an MRI that revealed inflammation on the outside of the knee capsule and the sprained ligament.

The Red Sox plan to have Bradley see team physician Dr. Peter Asnis in Boston on Monday before deciding if he will need to go on the 10-day disabled list.

"I think it's just to have extra eyes on it, have our doctors look at it and go from there," Bradley said after sitting out the Red Sox's come-from-behind 7-5 victory over the Detroit Tigers. "I feel a lot better. I already got some treatment on it. Feel like it's going in the right direction."

Bradley had struck a similarly upbeat tone Saturday after twisting his knee awkwardly and falling to the dirt. He walked off the field under his own power and said he "absolutely" would be able to play Sunday, joking that his legs can hold up under anything because "I'm built like Secretariat."

Red Sox manager John Farrell said the team would withhold a decision on Bradley's status until he sees the doctors at home. Bradley suggested the Sox want to make sure he can't do additional damage by playing through the injury.

"I feel like I can move around pretty good," Bradley said. "I think that's why they want the doctors to see it to kind of determine how much leeway they're going to let me have."

Steve Selsky started in center field in Bradley's place Sunday. Veteran outfield Chris Young also has considerable experience in center, but if Bradley is sidelined for a lengthy period of time, rookie Andrew Benintendi likely would move over from left field.

Bradley's absence coincided with the return of star right fielder Mookie Betts, who rejoined the Red Sox here Saturday and was cleared to play after missing three games with flu-like symptoms. Designated hitter/first baseman Hanley Ramirez remains in Boston with the flu and likely won't rejoin the team until Tuesday at Fenway Park.

Read the original:

Red Sox CF Jackie Bradley Jr. has sprained right knee ligament - ESPN

German direct-sell brand Canyon isnt a stranger to Trail Bike of the Year wins and top finishes, and the Spectral looked like the bike to beat when we began testing for this year's awards, especially considering the 1,900 alloy EX scooped a super rare five out of five earlier in the year and the bike's detailed features throughout make it a hard to beat complete package.

For a start, the CF chassis (2,199 separately) has a carbon-fibre mainframe and swingarm, rather than an alloy rear end, which immediately makes it one of the lightest bikes in this test despite matching the suspension travel of the heaviest bike here millimetre for millimetre.

Because youre buying it direct from Germany (but with a full UK support office) theres no compromise in componentry, and again the devil is in the detail. Items like the top-quality motocross-bred Renthal 780mm bar and 50mm stem that make the EX more extreme are obvious, but the Guide brakes on them are RS not just R. That means you get a Swing Link lever cam for more control and the 200mm front rotor boosts power, too.

The Pike fork is an RCT3 model featuring the awesome Charger damper, not the simpler Motion Control guts of the RC. The Monarch rear shock is an RT3 with extra compression tuning options for the already impeccably balanced suspension action. The RaceFace Turbine crank and DT Swiss Spline wheels are tighter and lighter than most here, too.

Triple-compound Maxxis High Roller II front and Minion SS rear tyres are also one of the best trail double acts around. The 66.5-degree steering angle and 455mm reach are totally on point for attacking descents and berms, but its steep enough in the seat for inching up climbs.

The result is a bike that just feels superb whatever youre doing. Off the leash and off the brakes itll launch down the most technical descents with quietly calm yet massively capable confidence. The harder you bury it into corners or the faster the drops and boulders come at you, the more those brake, suspension, tyre details and the sheer class of the frame become obvious. Suicidal becomes saveable and dodgy becomes doable.

As soon as the rocks stop flying and the trail points upwards it feels like an e-bike compared to the bikes it can match on the descents, with effortless pedalling efficiency and minimal leg-saving mass. That same lightweight agility makes it a blast to hustle through any trails and I simply cant think of a better example of a modern, state-of-the-art trail bike certainly not one at such an excellent value price, within a killer overall range.

This article was originally published in What Mountain Bike magazine, available on Apple Newsstand and Zinio.

Link:

Canyon Spectral CF 8.0 EX review - BikeRadar.com

The Chicago Fire Academy U-16 squad has arrived in Dallas to begin competition at the 10th edition of the Generation adidas Cup, an elite youth tournament that features 19 MLS club academies and 13 premier international clubs.

The Fire have been drawn into Group B within the Premier Division and open play on Friday (April 7) at 11:15 a.m. CT against Mexican side C.F. Monterrey. The match is available to watch live in the video player above as well as via Facebook Live stream on the official Chicago Fire club Facebook page.

The Fire will then complete group play with matches against the New England Revolution (Sunday, 9 a.m. CT) and Philadelphia Union (Tuesday, 11:15 a.m. CT).

For more on the tournament and a complete list of available live streams, visit MLSsoccer.com.

Premier Division

GROUP A

GROUP B

GROUP C

GROUP D

New York City FC

Chicago Fire

Columbus Crew SC

D.C. United

Seattle Sounders FC

New England Revolution

Orlando City SC

Houston Dynamo

Deportivo Saprissa

Philadelphia Union

San Jose Earthquakes

Portland Timbers

Pumas UNAM

C.F. Monterrey

C.D. Guadalajara

Tigres UANL

The rest is here:

Watch: Chicago Fire Academy U-16s face CF Monterrey - Chicago Fire

The technicals for CF Industries Holdings, Inc. (CF) have taken shape, and with them a comprehensive picture has emerged. This is the current state of play as presented by the current technical setup. The technical data for a stock offers a rich environment for establishing trading and investing decisions. By taking a keen examination of technical indicators, chart patterns and historical data, traders and investors can make crucial decisions.

(CF) has shown a marked change in trend levels over the course of recent market activity. Based on recent activity surrounding both the 50 and 200 SMAs, theres been a marked trend created which can be described as bullish. The composite picture painted by the trends built around both SMAs has also created a measured analysis of current investor sentiment as the stock navigates upside and downside risk. The established market sentiment toward the stock has created a trading environment which can suitably be described as positive. There has also been a knock-on effect as it relates to trading volume now reflected in weak real-time sentiment on the buying and selling curve; this has created in turn, indifference toward the stock as measured across a broad statistical mix of the general trading community.

As a composite and comprehensive tableau, the stocks position in the minds of the trading market reflects a broad analysis of technicals and inherent trends which underpin overall market-trading viability.

Relative strength indicator (RSI) and Stochastic measures are two very important leading indicators that help traders gauge overall movement of a particular stock; they act as boosters to technical analysis. Together they show in a measured way, whether or not a stock currently overbought or oversold. This indicator is crucial in determining whether traders are tipped toward the side of buying more of the stock, or doing the opposite and selling more of the stock. This is very important directional information necessary for making trading decisions. (CF)s current measure for its 14-day RSI is 47.36%; this is suggestive that on balance of the indicator, the stock is neutral neither overbought nor oversold and therefore not susceptible to any undue price movements in either direction. The stochastic picture presents a complimentary view of overall sentiment in the present state for (CF). Stochastic data gathered over the last 30 days has created a score of 36.82%. This indicates that the stock is neither overbought or oversold at current levels.

Often the indicators laid out above do not communicate fully all that a trader needs to know. In these instances, reliance can be placed upon chart indicators that provide a view of short-term movement and/or long term performance. The omens depict a telling picture in terms of the near-term trading setup for (CF); this makes things very interesting to the curious and interested eye. The +0.32 has created a positive in the trailing 30 days since initiating movement. Over the extended term, the stock has outperform the S&P 500 by -8.77%. This consistent movement and its attendant overall performance have produced higher daily volatility when compared with other stocks ranking in the same peer group and on the same exchange. The picture looks the same when the stock is assessed against volatility levels measured historically. This historical volatility gives a current reading of 34.76%. These measures of historic volatility are very handy in judging the underlying price momentum and the rate of change in the price of (CF). Bound up this picture of volatility, is another measure that gives the underlying thesis for (CF). This can best be seen by analyzing the readings for the stocks average true range, currently 3.51. ATR is a fine augment to the other indicators outlined above and should be used in conjunction and not as a standalone.

Read the original post:

What CF Industries Holdings, Inc. (CF) And Its Chart Reveal Today - NY Stock News

Valencia C.F. have won five of their last six La Liga games at Mestalla Stadium, including the match vs RC Celta Vigo, with the only setback a 1-1 draw against Sporting Gijon three rounds ago

Carlos Soler scored with a brilliant lob in the 86th minute for Valencia C.F. to beat Celta Vigo 3-2 in the Spanish La Liga on Thursday.

Soler received a pass outside the area and quickly flicked the ball over goalkeeper Sergio Alvarez, securing Valencia its second consecutive win at home.

Read more | At 101, India now above Thailand, Iraq, North Korea in Fifa rankings

Solers goal came only six minutes after Celta forward Iago Aspas equalized by converting a penalty kick.

Celta opened the scoring with a header by Gustavo Cabral following a free kick cross by Daniel Wass, but Dani Parejo equalized from close range in the 38th after a play that started with a back-heel pass by striker Simone Zaza.

Munir El Haddadi put Valencia ahead for the first time with a shot from inside the area in the 67th.

Read more | Juventus F.C. enter Italian Cup final despite 3-2 loss to Napoli SSC

Valencia has won five of its last six games at Mestalla Stadium, with the only setback a 1-1 draw against Sporting Gijon three rounds ago.

The result left Valencia 12th in the standings.

Celta was 10th. It has a game in hand, against league leader Real Madrid.

EIBAR BEATLAS PALMAS

Eibar moved closer to the fight for the Europa League spots.

Read more | Chelsea F.C. beat Manchester City F.C., Tottenham Hotspur F.C. still in hunt

The hosts got on the board through Bebe early, added to the lead with an own goal by Aythami Artiles in the 24th and secured the victory through Adrian Gonzalez in the 66th after Mauricio Lemos netted for Las Palmas with a superb free kick shot.

Eibar remained eighth in the 20-team standings, but its gap to seventh-placed Real Sociedad was only one point.

Read more | Pep Guardiola urges Manchester City players to prove their worth against Chelsea

The fifth- and sixth-place teams are secured in the Europa League next season, while the seventh-place team will advance if Barcelona beats Alaves in the Copa del Rey final in May.

Las Palmas, sitting 12th in the standings, hasnt won an away game since the first round.

Continue reading here:

Carlos Soler gives Valencia CF 3-2 win over RC Celta Vigo in Spanish La Liga - Hindustan Times

Cystic Fibrosis Ireland is again appealing to the government to approve ground-breaking therapies for people with the disease.

The plea comes ahead of Cystic Fibrosis National Awareness Week, which runs from 10-16 April.

The HSE has yet to confirm whether it will make Orkambi available - a life-changing drug that could significantly improve CF patients quality of life.

Chairperson of CF Galway, Mary Lane Heneghan is calling on the government to conclude its discussions with the drug manufacturer, Vertex Pharmaceuticals, and to give swift approval for the Orkambi therapy.

The drug is estimated to cost 159,000 per patient.

She said it is hard for CF patients and their families to listen to the issue being played out in the public eye.

Its not fair on the families and the people with CF out there that all of this is played out on the airwaves. I know it has to be, but its just very difficult for the parents and for the adults in particular.

Ms Lane Heneghan is hopeful the HSE will come to a decision by the end of this week.

The latest figures from the Cystic Fibrosis Registry of Ireland show that in 2015 there were 1,219 people registered with CF, with 19 years the median age.

65 Roses Day

65 Roses Day so-named after the way in which young children are first taught to say the words Cystic Fibrosis will see the country awash with purple next Thursday, 13 April as volunteers take to the streets and shopping centres selling purple roses with the aim of raising 100,000. Monies will go to fund the development of dedicated healthcare facilities, research, counselling and much-needed grant supports for people with CF in areas such as transplant assessment, fertility and bereavement.

Galway Events

It will be all guns blazing in Galway next week, according to Ms Lane Heneghan, with a number of events scheduled to take place in aid of CF.

TY students at St Brigids Vocational College Loughrea along with their TY Co-ordinator Ms Flanagan are organising an awareness and fundraising event on 13 April. There will also be a poker game in St Michael's Community Hall Craughwell on Friday 14, as well as a quiz in Dan's Bar Athenry organised by Ronan Cahill who is cycling Malin2Mizen for CF in May and an event in Mayfly Inn Oughterard plus a memorial walk to Mameam.

Eyre Square Shopping Centre, Bank of Ireland Oranmore and Londis Kilcolgan will also be selling 65 Roses.

Ms Lane Heneghan said they are totally dependent on the generosity of local people and she thanked those for continuing to support the organisation.

You can lend your support by buying a purple rose for 2, making a 2 text donation by texting 65ROSES to 50300 or donating online atwww.65rosesday.ie

Read more from the original source:

CF Ireland call for decision on life-saving drug - Galway Independent

Free Observer

Analyst Activity BMO Capital Markets Reiterates Buy on CF Industries Holdings (NYSE:CF) Market Exclusive Today, BMO Capital Markets reiterated its Buy rating on CF Industries Holdings (NYSE:CF) with a price target of $38.00. There are 2 sell ratings, 8 hold ratings, 4 buy ratings on the stock. The current consensus rating on CF Industries Holdings (NYSE ... Highly Traded Stock: CF Industries Holdings, Inc. (CF)HugoPress CF Industries Holdings, Inc. (CF): From Top to BottomStockNewsJournal CF Industries Holdings, Inc. surged in the Previous Trading Session with the Change of 2.85%Free Observer Equities.com -Herald KS -The USA Commerce all 24 news articles »

View post:

Analyst Activity BMO Capital Markets Reiterates Buy on CF Industries Holdings (NYSE:CF) - Market Exclusive